Literature DB >> 34664142

Surgery of the Primary Tumor in De Novo Metastatic Breast Cancer Confers No Survival Benefit: Author's Reply.

Kelly Stahl1, Daleela Dodge1, Chan Shen2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34664142     DOI： 10.1245/s10434-021-10906-1

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   5.344


× No keyword cloud information.
  5 in total

Review 1.  Bias in clinical intervention research.

Authors:  Lise Lotte Gluud
Journal:  Am J Epidemiol       Date:  2006-01-27       Impact factor: 4.897

2.  Surgery of the Primary Tumor in De Novo Metastatic Breast Cancer Confers No Survival Benefit.

Authors:  Sridevi Murali-Nanavati; Nita S Nair; Rajendra Badwe
Journal:  Ann Surg Oncol       Date:  2021-10-11       Impact factor: 5.344

3.  Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial.

Authors:  Rajendra Badwe; Rohini Hawaldar; Nita Nair; Rucha Kaushik; Vani Parmar; Shabina Siddique; Ashwini Budrukkar; Indraneel Mittra; Sudeep Gupta
Journal:  Lancet Oncol       Date:  2015-09-09       Impact factor: 41.316

4.  Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01.

Authors:  Atilla Soran; Vahit Ozmen; Serdar Ozbas; Hasan Karanlik; Mahmut Muslumanoglu; Abdullah Igci; Zafer Canturk; Zafer Utkan; Cihangir Ozaslan; Turkkan Evrensel; Cihan Uras; Erol Aksaz; Aykut Soyder; Umit Ugurlu; Cavit Col; Neslihan Cabioglu; Betül Bozkurt; Ali Uzunkoy; Neset Koksal; Bahadir M Gulluoglu; Bulent Unal; Can Atalay; Emin Yıldırım; Ergun Erdem; Semra Salimoglu; Atakan Sezer; Ayhan Koyuncu; Gunay Gurleyik; Haluk Alagol; Nalan Ulufi; Uğur Berberoglu; Mustafa Dulger; Omer Cengiz; Efe Sezgin; Ronald Johnson
Journal:  Ann Surg Oncol       Date:  2018-05-17       Impact factor: 5.344

5.  Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial.

Authors:  Florian Fitzal; Vesna Bjelic-Radisic; Michael Knauer; Günther Steger; Michael Hubalek; Marija Balic; Christian Singer; Rupert Bartsch; Peter Schrenk; Lidija Soelkner; Richard Greil; Michael Gnant
Journal:  Ann Surg       Date:  2019-06       Impact factor: 12.969
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.